REal-time Data Monitoring for Shared Adaptive, Multi-domain and Personalised Prediction and Decision Making for Long-term Pulmonary Care Ecosystems (RE-SAMPLE)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04955080

Acronym

RE-SAMPLE

Enrollment

216

Registered

2021-07-08

Start date

2022-01-24

Completion date

2025-09-01

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comorbidities and Coexisting Conditions, Exacerbation Copd, Pulmonary Disease, Chronic Obstructive

Brief summary

The main objective of this RE-SAMPLE cohort study is to identify from a real-world data (RWD) set that will be collected, a subset of data that can be potentially used as important predictors and parameters for disease progression of COPD and complex chronic conditions, and multi-morbid exacerbations. The secondary objective is to evaluate the feasibility of RWD collection from a patient's perspective. Study design: This is a prospective observational cohort study to collect RWD in patients with COPD and complex chronic conditions, with a maximum of 38 months of follow-up. Measurements are performed and RWD are collected by using the Healthentia mobile phone application at baseline (e.g. patient characteristics), daily (e.g. symptom diary), during follow-up visits and at deterioration, and from hospital data (e.g. healthcare visits). The choice of parameters and measurement tools that will be collected during the cohort will be updated every three months during the first year of the cohort (via protocol amendments). These updates are based on citizen-design sessions and on new literature insights. Prognostic models will be developed including predictors derived from the RWD collection.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of COPD according to the GOLD criteria \[5\] (FEV1 \< 80% of the predicted value and FEV1/FVC \< 0.70); * Patients can be included both at stable state and during exacerbation/hospitalization; * At least one comorbidity: diabetes mellitus (glucocorticoid-induced, or stable type 1 or 2), chronic heart failure (clinical diagnosis according to the ESC guidelines), ischaemic heart disease (history of myocardial infarction, angina pectoris), active symptoms of anxiety and/or depression (≥11 Hospital Anxiety and Depression Scale , and/or anxiety or depression symptoms being treated at the time of inclusion); * Under treatment at one of the pilot sites (MST, TUK, GEM); * \>40 years of age; * Smoker or ex-smoker; * Able to understand, read and write the language spoken in the country of the pilot site. * Accessibility to internet; * Written informed consent from the subject prior to participation. Furthermore, 25% of the patients should also have ≥ 2 exacerbations, defined as respiratory problems that required a course of oral corticosteroids / antibiotics in the two years preceding study entry; and/or ≥ 1 hospitalisation for respiratory problems in the two years preceding study entry; and/or modified MRC (mMRC) score of 3 or 4 (COPD patients with these scores have a higher chance of exacerbating).

Exclusion criteria

* Serious other diseases with a low survival rate; * Presence of any other active lung disease (e.g., sarcoidosis); * Severe psychiatric illness, diagnosed by anamnesis; * Maintenance therapy with antibiotics * Patients with cognitive impairment (Mini Mental State Examination (MMSE) \< 24)

Design outcomes

Primary

Measure	Time frame	Description
Predictors for exacerbations of COPD and comorbidities	Through study completion, an average of 2.5 years.	Prognostic performance of the validated predictive model for COPD and comorbid exacerbations and disease progression from RWD. The measures for progression will be survival, based on all-cause mortality, as well as morbidity. Morbidity is defined as time until first hospitalisation for an acute exacerbation of COPD and CCC, time until first moderate COPD exacerbation, time until first pneumonia, and total number of COPD and CCC exacerbations (extracted from daily symptom diaries) and pneumonia.

Secondary

Measure	Time frame	Description
Feasibility of the RWD collection.	Through study completion, an average of 1 year.	This relates to the usability of the application for data collection. The system usability scale will be used as a benchmarking tool that measures the level of usability.

Countries

Netherlands

Outcome results